Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 25722197.
- Also identified by DOI 10.1093/cid/civ155 and PMC identifier 4542662.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
Medical subject headings
- Antitubercular Agents
- Arylamine N-Acetyltransferase
- Benzoxazines
- Cytochrome P-450 CYP2B6
- Rifampin
- Tuberculosis